Elisa Agostinetto

Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...

50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social

YouTube video by OncoAlert 360 Oncology Here and Now podcast (Breast Cancer) S02E03 w/ Dr. Erika Hamilton and Dr. Elisa Agostinetto

Oncology Here & NOW S2E3 in #BreastCancer
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:

✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig

The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin

I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social

No strain, no formate gains - Nature Reviews Cancer In a study published in Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota and anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality.

#ResearchHighlight

In a study published in #Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota & anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality.

👇

YouTube video by OncoAlert 360 The OncoAlert 🚨Weekly Round Up July 11-17, 2025 (VIDEO)

The OncoAlert WEEKLY RoundUp 🚨
Covering TOP of the week July 11-17
www.youtube.com/watch?v=N9lO...

REGISTER👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social
@drnataliagandur.bsky.social

ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium | COR2ED In this conference update video, Profs. Wolfgang Janni, Sherko Kümmel and Michail Ignatiadis provide key insights from the highly anticipated ESMO Breast

📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium

Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer

cor2ed.com/n-connect/pr...

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only

The OncoAlert🚨NEWSLETTER
⭐️COMPLETE #ASCO25 EDITION

⭐️REGISTER
👉 oncoalert360.com
👉 buff.ly/48Xpgz0

@erikahamilton9.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@hoperugo.bsky.social

ECO & IPOS bring you a powerful online roundtable exploring how empathy shapes cancer care, and how we can better support the professionals delivering it.

Join the discussion on 🗓️ Tuesday, 25 June at 🕓 16:00–17:30 CEST.

Register now 🔗 www.europeancancer.org/events/363:y...

Are you a young oncologist attending #ASCO25?

Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫

Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...

@oncoalert.bsky.social
@ascocancer.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸

@elisaagostinetto.bsky.social‬
@erikahamilton9.bsky.social‬
@drsgraff.bsky.social‬
@elisabettabonzano.bsky.social‬

YouTube video by OncoAlert 360 The OncoAlert Oncology Round Up May 15-22, 2025 Top Oncology Breakthroughs in less than 5 Min!

The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025

REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/xgIw0BISCpo

@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social

VJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO Breast 2025 Poddavsnitt · OncoAlert · 2025-05-16 · 3 min

The VJ OA Oncology Journal Club
Dr. Evandro de Azambuja discussing APHINITY in #BreastCancer now on APPLE PODCASTS

podcasts.apple.com/se/podcast/o...

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@icromeattini.bsky.social
@maryamlustberg.bsky.social

Dr. Evandro de Azambuja discusses the final analysis of the APHINITY Breast Cancer trial just presented at ESMO Breast 2025. VJ OA Oncology Journal Club: Final Results of the APHINITY Breast Cancer Trial Presented at ESMO ...

The @OncoAlert 🚨 @VJOncology JOURNAL CLUB
Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25
youtu.be/ydcXe_faQH0

A sub analysis was just published out on European Journal of Cancer:

#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social

Right before the start of #ESMOBreast25, our last article is now out in #EJC

In this sub-analysis of the APHINITY trial led by @ChiaraDauccia, overweight/obesity was associated with poorer survival outcomes

50-days free access link👇🏻
authors.elsevier.com/a/1l5DL3QE--...

@oncoalert.bsky.social

The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025

REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

✅DESTINY-Breast11 Update from Industry
✅PEACE V STORM in #Prostate Cancer⛈️🕊️☢️
✅OS🧬EGFR-mutant Advanced🫁Non-Small Cell #LungCancer Treated with 1L Osimertinib
and more

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

www.thelancet.com/journals/lan...

Findings provide robust evidence to guide counselling and management decisions for young BRCA carriers with prior breast cancer

NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update

DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen

www.astrazeneca.com/media-centre...

VJ/OA Oncology Journal Club (Breast Cancer): Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer with Dr. Magaton Poddavsnitt · OncoAlert · 2025-05-02 · 5 min

Join @OncoAlert 🚨& @VJOncology Journal Club Discussing : Assisted reproductive technology in young BRCA carriers with a pregnancy after #BreastCancer

podcasts.apple.com/se/podcast/o...

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social

Oncology Here & Now Podcast Introducing the OncoAlert Podcast, where oncology experts discuss the latest and most impactful research in the field. Tune in every 10 days for new episodes, each focusing on a different tumor type, ...

Join Us at Oncology Here & Now
www.oncoalert360.com/12789765039p...

@elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @biagioricciutimd.bsky.social @barbaramelao.bsky.social
@weoncologists.bsky.social @drsgraff.bsky.social @erikahamilton9.bsky.social

I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...

Dear Colleagues,Welcome to the OncoAlert Weekly Round up Covering the TOP News and Trials THIS WEEK in Oncology. This week:Prognostic implications of risk de... The OncoAlert Weekly Round Up April 3-10, 2025

The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

youtu.be/l_jcTe69cCs

@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social

The #AURORA Data Analysis Committee is in Florence for a “datathon”! Over the next 2 days, PIs, bioinformaticians, clinicians, and BIG HQ are working together on analyses to advance a new AURORA manuscript. @aftimosp.bsky.social
@elisaagostinetto.bsky.social

Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠
Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻

@oncoalert.bsky.social

doi.org/10.1016/j.br...

YouTube video by OncoAlert 360 Oncology Here & Now: Supportive Care/ Telehealth with Dr. Joseph McCollom & Dr. Cristiane Bergerot

Oncology HERE & NOW Webcast/Podcast Now Out

JOIN Faulty 🚨 @realbowtiedoc.bsky.social 🇺🇸&
@crisbergerot.bsky.social 🇧🇷 as they dive into #SupportiveCare , the future of #Telemedicine and much more!

youtu.be/4WYdTostU7w

Effect of BMI on #BreastCancer stage and #BreastCancer specific survival

link.springer.com/article/10.1...

Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients.
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social

Now out a new episode of Oncology Here&Now, a podcast by @oncoalert.bsky.social 🎙️

I had the pleasure to discuss with @maryamlustberg.bsky.social about adjuvant CDK4/6i, including:
🔸how to choose between abema and ribo
🔸how to manage progression during or after adj CDK4/6i
🔸Male breast cancer!

Free & On Demand Breast Cancer UPDATE Brought to you by OncoAlert & Partners
DIRECT LINK/WATCH HERE👉 buff.ly/myqd20R

Join the Breast Cancer Faculty
@hoperugo.bsky.social
@drsgraff.bsky.social
@erikahamilton9.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social